Researcher profile
Camilla Hoyos
Affiliations
Organizations
Public evidence
3 connected articles
Evaluating possible 'next day' impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trial.2024 · Europe PMCCannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial.2023 · PubMed Central Open AccessOrally administered cannabidiol does not produce false-positive tests for Δ<sup>9</sup> -tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000.2022 · Europe PMC
Registered research
Connected studies
Matched by exact identifiers only. Profile data: ORCID. Last retrieved 09/09/2026.